Related Experiment Videos
Application of beta-interferon in virus-induced papillomas
1Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan.
The Journal of Investigative Dermatology
|December 1, 1990
Summary
Intralesional fibroblast interferon injections effectively treated common warts, with over 81% of treated extremities showing improvement compared to only 17% for placebo. This study highlights interferon
Area of Science:
- Dermatology
- Virology
- Immunology
Background:
- Common warts are caused by human papillomavirus (HPV).
- Existing treatments for warts have variable efficacy and potential side effects.
- Interferons are cytokines with antiviral and immunomodulatory properties.
Purpose of the Study:
- To evaluate the efficacy of intralesional human fibroblast interferon in treating common warts.
- To assess the effectiveness of interferon beta for epidermodysplasia verruciformis and flat warts.
Main Methods:
- A randomized, placebo-controlled study involving 80 patients with bilateral common warts.
- Patients received weekly intralesional injections of either human fibroblast interferon (0.1 X 10(6) units) or placebo into warts on opposing extremities.
- Therapy continued until warts cleared or for a maximum of 10 injections; warts were measured weekly.
Main Results:
- Over 81% of interferon-treated extremities showed cure or effective response, compared to 17% for placebo-treated extremities.
- The average number of interferon injections required for cure was 5.9 ± 1.7.
- Intralesional interferon beta showed some efficacy for epidermodysplasia verruciformis lesions, while subcutaneous interferon beta was effective in 45% of flat wart patients.
Conclusions:
- Intralesional human fibroblast interferon is an effective treatment for common warts with no observed adverse effects.
- Interferon beta demonstrates potential therapeutic value for specific HPV-related skin conditions like epidermodysplasia verruciformis and flat warts.